Association of MRC-1 and IL-28Bwith the treatment outcome of hepatitis C: a case control study

BMC Gastroenterology

Research Article

Cheng-Yuan Peng¹  Yun-Ping Lim²  Wen-Ling Liao³  Wei-Yong Lin³  Ter-Hsin Chen⁴  Fuu-Jen Tsai⁵  Lei Wan⁶ 

[1] Department of Internal Medicine, China Medical University Hospital, 40402, Taichung, Taiwan;Department of Pharmacy, College of Pharmacy, China Medical University, 40402, Taichung, Taiwan;Graduate Institute of Integrated Medicine, China Medical University, 40402, Taichung, Taiwan;Graduate Institute of Veterinary Pathobiology, College of Veterinary Medicine, National Chung Hsing University, Taichung, Taiwan;School of Chinese Medicine, China Medical University, No. 91, Hsueh-Shih Road, 40402, Taichung, Taiwan;School of Chinese Medicine, China Medical University, No. 91, Hsueh-Shih Road, 40402, Taichung, Taiwan;Department of Gynecology, China Medical University Hospital, 40447, Taichung, Taiwan;Department of Biotechnology, Asia University, 41354, Taichung, Taiwan;

关键词: Hepatitis C virus;    Standard of care treatment;    Sustained virological response;    Mannose receptor C;    Interleukin-28B;   

DOI  :  10.1186/1471-230X-14-113

 received in 2013-04-10, accepted in 2014-06-03,  发布年份 2014

来源: Springer

【 摘 要 】

BackgroundThe aim of this study was to evaluate whether polymorphisms of the mannose receptor C type 1 (MRC-1) and interleukin 28B (IL-28B) genes are associated with the treatment outcome of patients infected with hepatitis C virus genotypes 1 and 2 (HCV-1 and HCV-2, respectively) who are treated with peginterferon plus ribavirin (PEG-IFNα-RBV).MethodsWe analyzed the association of the patients’ sustained viral responses (SVRs) to PEG-IFNα-RBV therapy with 2 single nucleotide polymorphisms (SNPs) in MRC-1 and 3 SNPs in IL-28B. We selected patients infected with either HCV-1 (n = 265) or HCV-2 (n = 195) with or without SVR.ResultsAmong the MRC-1 SNPs, rs691005 was found to be associated with SVR in HCV-1-infected patients (P < 0.0001). The IL-28B rs8099917 SNP was found to be associated with SVR in HCV-1- and HCV-2-infected patients (HCV-1, P < 0.0001; HCV-2, P = 0.002), while IL-28B rs955155 and rs10853728 SNPs were found to be associated with SVR in HCV-1-infected patients (P = 0.003) and HCV-2-infected patients (P = 0.02), respectively. We also identified an interaction between MRC-1 rs691005 and IL-28B rs8099917 (P = 0.001). The C-T haplotype was shown to have a positive effect on SVR in HCV-1-infected patients (OR = 1.77, 95% CI = 1.2, 2.62), whereas the T-G haplotype was shown to have a negative effect on SVR in HCV-1-infected patients (OR = 0.28, 95% CI = 0.14, 0.58).ConclusionsThese results suggest that SNPs of IL-28B and MRC-1 can be used as genetic markers for predicting the outcome of PEG-IFNα-RBV treatment of HCV infections.

【 授权许可】

Unknown   
© Peng et al.; licensee BioMed Central Ltd. 2014. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.